Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM

This study is currently recruiting participants.
Verified November 2013 by Stanford University
Sponsor:
Collaborator:
National Comprehensive Cancer Network
Information provided by (Responsible Party):
Michaela Liedtke, Stanford University
ClinicalTrials.gov Identifier:
NCT01114282
First received: April 29, 2010
Last updated: November 10, 2013
Last verified: November 2013

April 29, 2010
November 10, 2013
August 2010
June 2014   (final data collection date for primary outcome measure)
The maximum tolerated dose (MTD) for the combination of pralatrexate with VELCADE in previously treated adult patients with multiple myeloma. [ Time Frame: assessed upon completion of cycle 1 of treatment ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01114282 on ClinicalTrials.gov Archive Site
  • Clinical evidence of anti-tumor activity based on response rates [ Time Frame: assessed after each 4 week cycle (up to 4 cycles) ] [ Designated as safety issue: No ]
  • Time to progression (TTP) [ Time Frame: assessed after each 4 week cycle (up to 4 cycles) and every 3 months for the first 2 years from protocol registration, every 6 months for years 3-5 and annually thereafter ] [ Designated as safety issue: No ]
  • Duration of Response Outcome [ Time Frame: assessed after each 4 week cycle (up to 4 cycles) and every 3 months for the first 2 years from protocol registration, every 6 months for years 3-5 and annually thereafter ] [ Designated as safety issue: No ]
  • Progression free survival (PFS) [ Time Frame: assessed after each 4 week cycle (up to 4 cycles) and every 3 months for the first 2 years from protocol registration, every 6 months for years 3-5 and annually thereafter ] [ Designated as safety issue: No ]
  • Overall survival (OS) [ Time Frame: assessed after each 4 week cycle (up to 4 cycles) and every 3 months for the first 2 years from protocol registration, every 6 months for years 3-5 and annually thereafter ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM
A Phase I Study of Bortezomib (VELCADE) in Combination With Pralatrexate in Relapsed/Refractory Multiple Myeloma

This is an open-label Phase I dose-escalation safety study of VELCADE in combination with pralatrexate in patients with previously treated multiple myeloma. In a standard 3+3 dose escalation trial design, escalating doses of pralatrexate in combination with VELCADE will be studied sequentially, with at least 3 patients in each dose level until the MTD is determined. Dose limiting toxicity (DLT) and MTD are determined during cycle 1 of treatment.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Multiple Myeloma
  • Drug: velcade
  • Drug: Pralatrexate
Experimental: VELCADE with pralatrexate
Pralatrexate,10 mg/m2, IV bolus on days 1, 8, and 15 VELCADE,1.3 mg/m2, IV bolus on days 1, 8, and 15
Interventions:
  • Drug: velcade
  • Drug: Pralatrexate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
28
June 2015
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • The patient has relapsed or refractory multiple myeloma that has progressed following at least on prior therapy.
  • Relapsed myeloma is defined in patients as at least 25% increasing monoclonal (M)-protein in serum or urine or in the size of a plasmacytoma compared to a best response reached after previous therapy.
  • Refractory myeloma is defined as failure to achieve at least a minor response (patient achieved stable disease as his/her best response) or progression of disease on current therapy or within 60 days of last dose of current therapy.
  • The patient has measurable disease defined as one of the following:

    1. serum M-protein >=1 g/dL
    2. urine M-protein >=200 mg/24 hours
  • Must have received at least one (1) prior line of systemic treatment that may have included VELCADE.

    a. NOTE: Patients may have undergone prior allogeneic or autologous stem cell transplantation (stem cell transplant with high dose induction chemotherapy with/without planned maintenance therapy will be considered one line of therapy).

  • No cytotoxic chemotherapy within 4 weeks prior to registration for protocol therapy.

    a. NOTE: this interval may be reduced to 14 days for thalidomide, lenalidomide, VELCADE or corticosteroids, provided other entry criteria are met.

  • No concurrent steroid use in doses greater than 10 mg daily of Prednisone (or equivalent) if given for management of co-morbid conditions.
  • Age >= 18 at the time of consent.
  • The patient has a life expectancy of more than 3 months.
  • No known central nervous system involvement by myeloma.
  • ECOG performance status 0-2.
  • No poorly controlled intercurrent illness including, but not limited to, ongoing or active infection, poorly controlled diabetes, symptomatic congestive heart failure, or psychiatric illness that in the opinion of the investigator would limit compliance with study requirements.
  • Patients must have adequate bone marrow function: Platelets >100 x 109/L, Hemoglobin > 8.0g/dL and ANC > 1 x 109/L
  • Patients must have adequate liver functions: AST and ALT < 2.5 X upper limit of normal, Total bilirubin <= 1.5 x ULN
  • Patients must have adequate renal function defined as creatinine clearance of 30 ml/minute (Cockcroft-Gault).
  • The patient must have been on a regimen of 1.0 - 1.25 mg PO QD of folic acid for at least 10 days prior to the planned start of pralatrexate and received 1 mg IM of vitamin B12 within 10 weeks of the planned start of pralatrexate.
  • Patients with reproductive potential must use an effective method of contraception to avoid pregnancy for the duration of the trial.
  • If female of childbearing potential, pregnancy test must be negative within 7 days prior to registration for protocol therapy.
  • Ability to understand and the willingness to sign a written informed consent document including HIPAA authorization for release of personal health information.
  • The patient must be willing and able to receive outpatient treatment and laboratory monitoring at the Stanford Cancer Center.

Exclusion Criteria:

  • The patient has nonmeasurable multiple myeloma, defined as less than 1g/dl M-protein in serum and less than 200 mg/24 hours M-protein in urine.
  • The patient received glucocorticoid therapy (prednisone > 10 mg/day orally or equivalent) within the last 2 weeks prior to the first dose of study drug.
  • The patient received chemotherapy with approved or investigative anticancer therapeutics within 4 weeks.

    a. NOTE: this interval may be reduced to 14 days for thalidomide, lenalidomide, VELCADE or corticosteroids, provided other entry criteria are met.

  • The patient has an acute infection requiring systemic antibiotics, antiviral agents, or antifungal agents within 2 weeks before the first dose of study drug.
  • The patient has grade 2 or higher neuropathy within 14 days of enrollment.
  • The patient has any serious psychiatric or medical condition that could interfere with treatment and study procedures, place the patient at unacceptable risk, or confound the ability of investigators to interpret study data.
  • The patient is a pregnant or lactating woman.
  • Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (see Appendix A), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the Investigator as not medically relevant.
  • Patient has hypersensitivity to VELCADE, boron or mannitol.
  • Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.
Both
18 Years and older
No
Contact: Vani Jain (650) 725-5459 vani@stanford.edu
United States
 
NCT01114282
HEMMYL0014, SU-04282010-5783
Not Provided
Michaela Liedtke, Stanford University
Michaela Liedtke
National Comprehensive Cancer Network
Principal Investigator: Michaela Liedtke Stanford University
Stanford University
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP